The Recruitment of Systemic-to-Pulmonary Arterial Collaterals in Chronic and Severe Precapillary Pulmonary Hypertension as an Adaptive or Misguided Mechanism
BACKGROUND: The clinical impact of systemic-to-pulmonary arterial collaterals (SPCs) across pulmonary hypertension (PH) groups remains unclear. The authors evaluated the prevalence, clinical correlates, and prognostic relevance of SPCs in a comprehensive PH cohort. METHODS: The authors retrospectively analyzed 434 adult PH patients diagnosed per European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines. Baseline risk was evaluated using multiparametric risk scores. All patients underwent diagnostic heart catheterization and angiography, with SPC recruitment semi-quantitatively graded from 0 (none) to 3 (severe, high grade: 2-3). RESULTS: Mean age was 51.9 ± 18.2 years (61.1% female; groups 1, 2, 3, and 4 comprised 51.6%, 3.4%, 10.1%, and 33.2%, respectively). High-grade SPCs were significantly more prevalent in group 4 (58.3%) compared to groups 1 (30.4%), 2 (20.0%), and 3 (6.8%) (P <.001). Higher SPC grade significantly correlated with PH severity across clinical, echocardiographic, hemodynamic, and risk score measures (P <.001). Although higher SPC grades were linked to clinical worsening requiring parenteral prostacyclins (P = .027), they were not associated with overall 5-year survival, regardless of pulmonary vascular resistance severity or non-CTEPH etiology (P = .920). Only the Registry to Evaluate Early and Long-Term PAH Disease Management 2.0 score independently predicted mortality (hazard ratio [HR] = 1.19, P <.001, 95% CI: 1.13-1.26). CONCLUSION: Systemic-to-pulmonary arterial collaterals are recruited across all PH etiology groups beyond group 4. While SPC recruitment serves as a marker of advanced pulmonary vascular involvement and elevated risk status, it does not act as an independent driver of long-term mortality.
Authors
- Zübeyde Bayram (ORCID: https://orcid.org/0000-0003-4546-1452)
- Barkın Kültürsay (ORCID: https://orcid.org/0000-0002-1424-2209)
- Seda Tanyeri (ORCID: https://orcid.org/0000-0002-0933-9233)
- Aykun Hakgör (ORCID: https://orcid.org/0000-0001-8252-0373)
- Çağlar Emre Çağlıyan (ORCID: https://orcid.org/0000-0002-2529-4995)
- Berhan Keskin (ORCID: https://orcid.org/0000-0002-5879-2245)
- Ali Karagöz (ORCID: https://orcid.org/0000-0002-0438-2021)
- İbrahi̇m Hali̇l Tanboğa (ORCID: https://orcid.org/0000-0003-4546-9227)
- Dicle Sırma (ORCID: https://orcid.org/0000-0002-0317-8838)
- Cıhangır Kaymaz (ORCID: https://orcid.org/0000-0003-2627-9081)
- Tahsin Güneysu (ORCID: https://orcid.org/0009-0007-5443-5957)
- Hacer Ceren Tokgöz (ORCID: https://orcid.org/0000-0001-8187-7290)
- Çağdaş Buluş (ORCID: https://orcid.org/0000-0002-2433-3593)
- Nihal Özdemir (ORCID: https://orcid.org/0000-0002-6337-7716)
- Metehan Kibar (ORCID: https://orcid.org/0009-0004-2577-6355)
- Müge Ildızlı Demirbas (ORCID: https://orcid.org/0000-0003-2970-6616)
Institutions
- Başkent University (TR)
- Istanbul Medipol University (TR)
- Başkent University Hospital (TR)
- Kartal Koşuyolu High Specialization Training and Research Hospital (TR)
- Atlas Üniversitesi (TR)
- Cukurova University (TR)
Publication Details
- Journal
- The Anatolian Journal of Cardiology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.14744/anatoljcardiol.2026.6587
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00